CURRENT AFFAIRS

Detailed explanation-1: -Imvanex. There is one vaccine authorised for use against monkeypox disease in the EU, Imvanex. Imvanex has been authorised to protect adults from mpox disease in the EU since 22 July 2022. It is also authorised to protect people against diseases caused by the vaccinia virus.

Detailed explanation-2: -JYNNEOS is approved for the prevention of mpox disease in individuals 18 years of age and older at high risk for mpox infection. Licensure was supported by animal studies as well as clinical studies demonstrating a comparable immune response to ACAM2000 (Rao AK et al, MMWR, 2022; 71(22):734-742).

Detailed explanation-3: -In the United States, two vaccines (JYNNEOS and ACAM2000) may be used to prevent the spread of mpox. Both vaccines are expected to provide a good level of protection against mpox. The main vaccine being used against mpox during the 2022 mpox outbreak is JYNNEOS. JYNNEOS is a 2-dose vaccine.

Detailed explanation-4: -JYNNEOS is an attenuated, live, non-replicating smallpox and monkeypox vaccine that elicits humoral and cellular immune responses to orthopoxviruses. Vaccinia neutralizing antibody responses in humans were evaluated to establish the effectiveness of JYNNEOS for prevention of smallpox and monkeypox.

Detailed explanation-5: -Imvanex® is now also registered as a vaccine to protect against Mpox; the vaccine received EMA authorisation on 22 July 2022. Imvanex® contains a live attenuated virus that cannot replicate inside the body. It has milder side-effects than the old smallpox vaccinations, and Imvanex® does not leave a scar.